Smoking cessation, version 1.2016 clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 11, 2016, Pages 1430-1468

  Shields, Peter G ^a   Herbst, Roy S ^a   Arenberg, Douglas ^a   Benowitz, Neal L ^a   Bierut, Laura ^a   Luckart, Julie Bylund ^a   Cinciripini, Paul ^a   Collins, Bradley ^a   David, Sean ^a   Davis, James ^a   Hitsman, Brian ^a   Hyland, Andrew ^a   Lang, Margaret ^a   Leischow, Scott ^a   Park, Elyse R ^a   Purcell, W Thomas ^a   Selzle, Jill ^a   Silber, Andrea ^a   Spencer, Sharon ^a   Tanvetyanon, Tawee ^a   Tiep, Brian ^a   Tindle, Hilary A ^a   Tucker Seeley, Reginald ^a   Urbanic, James ^a   Hooper, Monica Webb ^a   Weksler, Benny ^a   Whitlock, C Will ^a   Wood, Douglas E ^a   Burns, Jennifer ^a   Scavone, Jillian ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CONSENSUS DEVELOPMENT; DEATH; HUMAN; ONCOLOGY; OVERALL SURVIVAL; SMOKING CESSATION; STANDARDS; STATISTICS AND NUMERICAL DATA;

HUMANS; MEDICAL ONCOLOGY; SMOKING CESSATION;

EID: 84994644624     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0152     Document Type: Review

References (260)

1. Jamal A, Agaku IT, O'Connor E, et al. Current cigarette smoking among adults - United States, 2005-2013. MMWR Morb Mortal Wkly Rep 2014;63:1108-1112.
2. The Health Consequences of Smoking - 50 Years of Progress: A Report of the Surgeon General, 2014. Available at: http://www.surgeongeneral.gov/library/reports/50-years-of-progress/. Accessed October 18, 2016.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
4. Tseng TS, Lin HY, Moody-Thomas S, et al. Who tended to continue smoking after cancer diagnosis: the national health and nutrition examination survey 1999-2008. BMC Public Health 2012;12:784.
5. Park ER, Japuntich SJ, Rigotti NA, et al. A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer 2012;118:3153-3164.
6. Underwood JM, Townsend JS, Tai E, et al. Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. J Cancer Surviv 2012;6:333-344.
7. Westmaas JL, Newton CC, Stevens VL, et al. Does a recent cancer diagnosis predict smoking cessation? An analysis from a large prospective US cohort. J Clin Oncol 2015;33:1647-1652.
8. Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers: findings from a nationwide survey nine years after diagnosis. Cancer Epidemiol Biomarkers Prev 2014;23:1783-1792.
9. Mayer DK, Carlson J. Smoking patterns in cancer survivors. Nicotine Tob Res 2011;13:34-40.
10. Toll BA, Brandon TH, Gritz ER, et al. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013;19:1941-1948.
11. Hanna N, Mulshine J, Wollins DS, et al. Tobacco cessation and control a decade later: American society of clinical oncology policy statement update. J Clin Oncol 2013;31:3147-3157.
12. Goldstein AO, Ripley-Moffitt CE, Pathman DE, Patsakham KM. Tobacco use treatment at the U.S. National Cancer Institute's designated Cancer Centers. Nicotine Tob Res 2013;15:52-58.
13. Barzilai DA, Goodwin MA, Zyzanski SJ, Stange KC. Does health habit counseling affect patient satisfaction? Prev Med 2001;33:595-599.
14. Conroy MB, Majchrzak NE, Regan S, et al. The association between patient-reported receipt of tobacco intervention at a primary care visit and smokers' satisfaction with their health care. Nicotine Tob Res 2005;7(SUPPL. 1):S29-34.
15. Weaver KE, Danhauer SC, Tooze JA, et al. Smoking cessation counseling beliefs and behaviors of outpatient oncology providers. Oncologist 2012;17:455-462.
16. Warren GW, Marshall JR, Cummings KM, et al. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract 2013;9:258-262.
17. Warren GW, Marshall JR, Cummings KM, et al. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. J Thorac Oncol 2013;8:543-548.
18. Warren GW, Dibaj S, Hutson A, et al. Identifying targeted strategies to improve smoking cessation support for cancer patients. J Thorac Oncol 2015;10:1532-1537.
19. Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005;14:2287-2293.
20. Peters EN, Torres E, Toll BA, et al. Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. J Clin Oncol 2012;30:2869-2875.
21. McAfee T, Babb S, McNabb S, Fiore MC. Helping smokers quit-opportunities created by the Affordable Care Act. N Engl J Med 2015;372:5-7.
22. Centers for Disease Control and Prevention (CDC). Quitting smoking among adults - United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011;60:1513-1519.
23. Twyman L, Bonevski B, Paul C, Bryant J. Perceived barriers to smoking cessation in selected vulnerable groups: a systematic review of the qualitative and quantitative literature. BMJ Open 2014;4:e006414.
24. Ramaswamy AT, Toll BA, Chagpar AB, Judson BL. Smoking, cessation, and cessation counseling in patients with cancer: a population-based analysis. Cancer 2016;122:1247-1253.
25. Chapple A, Ziebland S, McPherson A. Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. BMJ 2004;328:1470.
26. Schnoll RA, Malstrom M, James C, et al. Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns 2002;46:137-145.
27. Morgan G, Schnoll RA, Alfano CM, et al. National Cancer Institute conference on treating tobacco dependence at cancer centers. J Oncol Pract 2011;7:178-182.
28. Mazza R, Lina M, Boffi R, et al. Taking care of smoker cancer patients: a review and some recommendations. Ann Oncol 2010;21:1404-1409.
29. Aigner CJ, Cinciripini PM, Anderson KO, et al. The association of pain with smoking and quit attempts in an electronic diary study of cancer patients trying to quit. Nicotine Tob Res 2016;18:1449-1455.
30. Eng L, Qiu X, Su J, et al. The role of second-hand smoke exposure on smoking cessation in non-tobacco-related cancers. Cancer 2015;121:2655-2663.
31. Martinez E, Tatum KL, Weber DM, et al. Issues related to implementing a smoking cessation clinical trial for cancer patients. Cancer Causes Control 2009;20:97-104.
32. U.S. National Library of Medicine. Key MEDLINE® Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd-key.html. Accessed May 1, 2015.
33. Gritz ER, Fingeret MC, Vidrine DJ, et al. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 2006;106:17-27.
34. Tang MW, Oakley R, Dale C, et al. A surgeon led smoking cessation intervention in a head and neck cancer centre. BMC Health Serv Res 2014;14:636.
35. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013;5:CD000165.
36. Coleman T. ABC of smoking cessation. Use of simple advice and behavioural support. BMJ 2004;328:397-399.
37. Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction 2012;107:1066-1073.
38. Lee SM, Landry J, Jones PM, et al. The effectiveness of a perioperative smoking cessation program: a randomized clinical trial. Anesth Analg 2013;117:605-613.
39. Sobus SL, Warren G W. The biologic effects of cigarette smoke on cancer cells. Cancer 2014;120:3617-3626.
40. Rink M, Zabor EC, Furberg H, et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol 2013;64:456-464.
41. Ehdaie B, Furberg H, Zabor EC, et al. Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. BJU Int 2013;111:589-595.
42. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol 2015;70:458-466.
43. Braithwaite D, Izano M, Moore DH, et al. Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat 2012;136:521-533.
44. Boone SD, Baumgartner KB, Baumgartner RN, et al. Active and passive cigarette smoking and mortality among Hispanic and non-Hispanic white women diagnosed with invasive breast cancer. Ann Epidemiol 2015;25:824-831.
45. Waggoner SE, Darcy KM, Fuhrman B, et al. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol 2006;103:853-858.
46. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012;30:2102-2111.
47. Walter V, Jansen L, Hoffmeister M, Brenner H. Smoking and survival of colorectal cancer patients: systematic review and meta-analysis. Ann Oncol 2014;25:151-1525.
48. Walter V, Jansen L, Hoffmeister M, et al. Smoking and survival of colorectal cancer patients: population-based study from Germany. Int J Cancer 2015;137:1433-1445.
49. Modesitt SC, Huang B, Shelton BJ, Wyatt S. Endometrial cancer in Kentucky: the impact of age, smoking status, and rural residence. Gynecol Oncol 2006;103:300-306.
50. Kountourakis P, Correa AM, Hofstetter WL, et al. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer 2011;117:925-930.
51. Zheng Y, Cao X, Wen J, et al. Smoking affects treatment outcome in patients with resected esophageal squamous cell carcinoma who received chemotherapy. PLoS One 2015;10:e0123246.
52. Platek AJ, Jayaprakash V, Merzianu M, et al. Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation [published online ahead of print June 27, 2016]. Laryngoscope, doi: 10.1002/lary.26083.
53. Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma - a prospective study. Radiother Oncol 2012;103:38-44.
54. Sharp L, McDevitt J, Carsin AE, et al. Smoking at diagnosis is an independent prognostic factor for cancer-specific survival in head and neck cancer: findings from a large, population-based study. Cancer Epidemiol Biomarkers Prev 2014;23:2579-2590.
55. Ehdaie B, Furberg H, Zabor EC, et al. Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer. J Urol 2014;191:597-602.
56. Keizman D, Gottfried M, Ish-Shalom M, et al. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 2014;19:51-60.
57. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569.
58. Tao L, Wang R, Gao YT, Yuan JM. Impact of postdiagnosis smoking on long-term survival of cancer patients: the Shanghai cohort study. Cancer Epidemiol Biomarkers Prev 2013;22:2404-2411.
59. Warren GW, Kasza KA, Reid ME, et al. Smoking at diagnosis and survival in cancer patients. Int J Cancer 2013;132:401-410.
60. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004;125:27-37.
61. Kelemen LE, Warren GW, Koziak JM, et al. Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. Gynecol Oncol 2016;140:124-130.
62. Lin Y, Yagyu K, Ueda J, et al. Active and passive smoking and risk of death from pancreatic cancer: findings from the Japan Collaborative Cohort Study. Pancreatology 2013;13:279-284.
63. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA 2011;305:2548-2555.
64. Chelghoum Y, Danaila C, Belhabri A, et al. Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol 2002;13:1621-1627.
65. Ramamoorthy S, Luo L, Luo E, Carethers JM. Tobacco smoking and risk of recurrence for squamous cell cancer of the anus. Cancer Detect Prev 2008;32:116-120.
66. Wyszynski A, Tanyos SA, Rees JR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer 2014;120:408-414.
67. Ogihara K, Kikuchi E, Yuge K, et al. Refraining from smoking for 15 years or more reduced the risk of tumor recurrence in non-muscle invasive bladder cancer patients. Ann Surg Oncol 2016;23:1752-1759.
68. Bishop JD, Killelea BK, Chagpar AB, et al. Smoking and breast cancer recurrence after breast conservation therapy. Int J Breast Cancer 2014;2014:327081.
69. Han MA, Kim YW, Choi IJ, et al. Association of smoking history with cancer recurrence and survival in stage III-IV male gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2013;22:1805-1812.
70. Joshu CE, Mondul AM, Meinhold CL, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst 2011;103:835-838.
71. Moreira DM, Aronson WJ, Terris MK, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer 2014;120:197-204.
72. Rieken M, Shariat SF, Kluth LA, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol 2015;68:949-956.
73. Boyle JM, Tandberg DJ, Chino J P, et al. Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis. Cancer 2015;121:598-604.
74. Shiels MS, Gibson T, Sampson J, et al. Cigarette smoking prior to first cancer and risk of second smoking-associated cancers among survivors of bladder, kidney, head and neck, and stage I lung cancers. J Clin Oncol 2014;32:3989-3995.
75. Ford MB, Sigurdson AJ, Petrulis ES, et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 2003;98:1457-1464.
76. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995;87:1530-1537.
77. Balduyck B, Sardari Nia P, Cogen A, et al. The effect of smoking cessation on quality of life after lung cancer surgery. Eur J Cardiothorac Surg 2011;40:1432-1437; discussion 1437-1438
78. Erhunmwunsee L, Onaitis MW. Smoking cessation and the success of lung cancer surgery. Curr Oncol Rep 2009;11:269-274.
79. Mason DP, Subramanian S, Nowicki ER, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. Ann Thorac Surg 2009;88:362-370; discussion 370-361
80. Gajdos C, Hawn MT, Campagna EJ, et al. Adverse effects of smoking on postoperative outcomes in cancer patients. Ann Surg Oncol 2012;19:1430-1438.
81. Sharma A, Deeb A P, Iannuzzi JC, et al. Tobacco smoking and postoperative outcomes after colorectal surgery. Ann Surg 2013;258:296-300.
82. Ehlers SL, Gastineau DA, Patten CA, et al. The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia. Bone Marrow Transplant 2011;46:285-290.
83. Chang DW, Reece GP, Wang B, et al. Effect of smoking on complications in patients undergoing free TRAM flap breast reconstruction. Plast Reconstr Surg 2000;105:2374-2380.
84. Spear SL, Ducic I, Cuoco F, Hannan C. The effect of smoking on flap and donor-site complications in pedicled TRAM breast reconstruction. Plast Reconstr Surg 2005;116:1873-1880.
85. Marin VP, Pytynia KB, Langstein HN, et al. Serum cotinine concentration and wound complications in head and neck reconstruction. Plast Reconstr Surg 2008;121:451-457.
86. Chen AM, Chen LM, Vaughan A, et al. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys 2011;79:414-419.
87. Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993;328:159-163.
88. Zevallos JP, Mallen MJ, Lam CY, et al. Complications of radiotherapy in laryngopharyngeal cancer: effects of a prospective smoking cessation program. Cancer 2009;115:4636-4644.
89. Egestad H, Emaus N. Changes in health related quality of life in women and men undergoing radiation treatment for head and neck cancer and the impact of smoking status in the radiation treatment period. Eur J Oncol Nurs 2014;18:339-346.
90. Eifel PJ, Jhingran A, Bodurka DC, et al. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol 2002;20:3651-3657.
91. Kucera H, Enzelsberger H, Eppel W, Weghaupt K. The influence of nicotine abuse and diabetes mellitus on the results of primary irradiation in the treatment of carcinoma of the cervix. Cancer 1987;60:1-4.
92. Rades D, Setter C, Schild SE, Dunst J. Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;71:1134-1142.
93. Alsadius D, Hedelin M, Johansson KA, et al. Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer. Radiother Oncol 2011;101:495-501.
94. Steinberger E, Kollmeier M, McBride S, et al. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity. BJU Int 2015;116:596-603.
95. Pickles T, Liu M, Berthelet E, et al. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol 2004;171:1543-1546.
96. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99:365-375.
97. Tyc VL, Hudson MM, Hinds P, et al. Tobacco use among pediatric cancer patients: recommendations for developing clinical smoking interventions. J Clin Oncol 1997;15:2194-2204.
98. Tobacco Use During Cancer Treatment. American Society for Clinical Oncology; 2012. Available at: http://www.cancer.net/navigating-cancer-care/prevention-and-healthy-living/tobacco-use/tobacco-use-during-cancer-treatment. Accessed September 23, 2015.
99. Geng Y, Savage SM, Razani-Boroujerdi S, Sopori ML. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. J Immunol 1996;156:2384-2390.
100. Kalra R, Singh S P, Savage SM, et al. Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. J Pharmacol Exp Ther 2000;293:166-171.
101. Geng Y, Savage SM, Johnson LJ, et al. Effects of nicotine on the immune response. I. Chronic exposure to nicotine impairs antigen receptor-mediated signal transduction in lymphocytes. Toxicol Appl Pharmacol 1995;135:268-278.
102. Singh SP, Kalra R, Puttfarcken P, et al. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol Appl Pharmacol 2000;164:65-72.
103. Birrell MA, Wong S, Catley MC, Belvisi MG. Impact of tobacco-smoke on key signaling pathways in the innate immune response in lung macrophages. J Cell Physiol 2008;214:27-37.
104. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflamm Res 2008;57:497-503.
105. Kimura T, Shibata Y, Yamauchi K, et al. Oxidized phospholipid, 1-palmitoyl-2-(9'-oxo-nonanoyl)-glycerophosphocholine (PON-GPC), produced in the lung due to cigarette smoking, impairs immune function in macrophages. Lung 2012;190:169-182.
106. Ferson M, Edwards A, Lind A, et al. Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer 1979;23:603-609.
107. Tollerud DJ, Clark JW, Brown LM, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis 1989;139:194-198.
108. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004;164:2206-2216.
109. Nishioka T, Luo LY, Shen L, et al. Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Br J Cancer 2014;110:1785-792.
110. Zhang J, Kamdar O, Le W, et al. Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer. Am J Respir Cell Mol Biol 2009;40:135-146.
111. Zhao J, Xin M, Wang T, et al. Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation. Mol Cancer Res 2009;7:1954-1961.
112. Shen T, Le W, Yee A, et al. Nicotine induces resistance to chemotherapy in nasal epithelial cancer. Am J Rhinol Allergy 2010;24:e73-77.
113. Trevino JG, Pillai S, Kunigal S, et al. Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Neoplasia 2012;14:1102-1114.
114. Li H, Shi Q. Drugs and diseases interacting with cigarette smoking in US prescription drug labelling. Clin Pharmacokinet 2015;54:493-501.
115. O'Malley M, King AN, Conte M, et al. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol 2014;9:917-926.
116. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166-2171.
117. van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25:2719-2726.
118. Darwish M, Bond M, Hellriegel E, et al. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol 2015;75:1143-1154.
119. Treanda (bendamustine hydrochloride) [package insert]. North Wales, PA: Teva Pharmaceuticals; 2015. Available at: http://www.treandahcp.com/pdf/TREANDA-final-PI.pdf. Accessed July 15, 2016.
120. de Graan AJ, Loos WJ, Friberg LE, et al. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res 2012;18:4425-4432.
121. Peppone LJ, Mustian KM, Morrow GR, et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist 2011;16:1784-1792.
122. Danson SJ, Rowland C, Rowe R, et al. The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study. Support Care Cancer 2016;24:1507-1516.
123. Ditre JW, Gonzalez BD, Simmons VN, et al. Associations between pain and current smoking status among cancer patients. Pain 2011;152:60-65.
124. Gonzalez A, Japuntich S, Keating NL, et al. Pain experiences among a population-based cohort of current, former, and never regular smokers with lung and colorectal cancer. Cancer 2014;120:3554-3561.
125. Logan HL, Fillingim RB, Bartoshuk LM, et al. Smoking status and pain level among head and neck cancer patients. J Pain 2010;11:528-534.
126. Novy DM, Lam C, Gritz ER, et al. Distinguishing features of cancer patients who smoke: pain, symptom burden, and risk for opioid misuse. J Pain 2012;13:1058-1067.
127. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services; 1990. Available at: http://profiles.nlm.nih.gov/NN/B/B/C/T/. Accessed October 17, 2016.
128. Sitas F, Weber MF, Egger S, et al. Smoking cessation after cancer. J Clin Oncol 2014;32:3593-3595.
129. Johnston-Early A, Cohen MH, Minna JD, et al. Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980;244:2175-2179.
130. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823-829.
131. Roach MC, Rehman S, DeWees TA, et al. It's never too late: smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival. Pract Radiat Oncol 2016;6:12-18.
132. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999;86:2337-2345.
133. Dobson Amato KA, Hyland A, Reed R, et al. Tobacco cessation may improve lung cancer patient survival. J Thorac Oncol 2015;10:1014-1019.
134. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383-390.
135. Garces YI, Schroeder DR, Nirelli LM, et al. Second primary tumors following tobacco dependence treatments among head and neck cancer patients. Am J Clin Oncol 2007;30:531-539.
136. Amri R, Bordeianou LG, Sylla P, Berger DL. Does active smoking induce hematogenous metastatic spread in colon cancer? Am J Surg 2015;210:930-932.
137. Kuri M, Nakagawa M, Tanaka H, et al. Determination of the duration of preoperative smoking cessation to improve wound healing after head and neck surgery. Anesthesiology 2005;102:892-896.
138. Baser S, Shannon VR, Eapen GA, et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 2006;130:1784-1790.
139. Garces YI, Hays JT. Tobacco dependence: why should an oncologist care? J Clin Oncol 2003;21:1884-1886.
140. Land SR, Toll BA, Moinpour CM, et al. Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res 2016;22:1907-1913.
141. Warren GW, Marshall JR, Cummings KM, et al. Automated tobacco assessment and cessation support for cancer patients. Cancer 2014;120:562-569.
142. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-1127.
143. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change, 2nd ed. New York, NY: The Guilford Press; 2002.
144. Rollnick S, Miller WR, Butler CC. Motivational Interviewing in Health Care: Helping Patients Change Behavior, 1st ed. New York, NY: The Guilford Press; 2007.
145. Lindson-Hawley N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012;11:CD008033.
146. Lindson-Hawley N, Aveyard P, Hughes JR. Gradual reduction vs abrupt cessation as a smoking cessation strategy in smokers who want to quit. JAMA 2013;310:91-92.
147. Ostroff JS, Burkhalter JE, Cinciripini PM, et al. Randomized trial of a presurgical scheduled reduced smoking intervention for patients newly diagnosed with cancer. Health Psychol 2014;33:737-747.
148. Ehlers SL, Bronars CA, Patten CA, et al. Accuracy of self-reported tobacco use status among hematopoietic SCT patients. Bone Marrow Transplant 2014;49:961-965.
149. Hald J, Overgaard J, Grau C. Evaluation of objective measures of smoking status - a prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncol 2003;42:154-159.
150. Warren GW, Arnold SM, Valentino J P, et al. Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol 2012;103:45-48.
151. Jung KH, Kim SM, Choi MG, et al. Preoperative smoking cessation can reduce postoperative complications in gastric cancer surgery. Gastric Cancer 2015;18:683-690.
152. Yoshida N, Baba Y, Hiyoshi Y, et al. Duration of smoking cessation and postoperative morbidity after esophagectomy for esophageal cancer: how long should patients stop smoking before surgery? World J Surg 2016;40:142-147.
153. Theadom A, Cropley M. Effects of preoperative smoking cessation on the incidence and risk of intraoperative and postoperative complications in adult smokers: a systematic review. Tob Control 2006;15:352-358.
154. Thomsen T, Villebro N, Moller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev 2014;3:CD002294.
155. Wong J, Abrishami A, Yang Y, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. Anesthesiology 2012;117:755-764.
156. Moller AM, Villebro N, Pedersen T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002;359:114-117.
157. Lindstrom D, Sadr Azodi O, Wladis A, et al. Effects of a perioperative smoking cessation intervention on postoperative complications: a randomized trial. Ann Surg 2008;248:739-745.
158. Sorensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. Ann Surg 2012;255:1069-1079.
159. Sorensen LT, Karlsmark T, Gottrup F. Abstinence from smoking reduces incisional wound infection: a randomized controlled trial. Ann Surg 2003;238:1-5.
160. Sorensen LT, Jorgensen LN, Zillmer R, et al. Transdermal nicotine patch enhances type I collagen synthesis in abstinent smokers. Wound Repair Regen 2006;14:247-251.
161. Bottorff JL, Seaton CL, Viney N, et al. The Stop Smoking Before Surgery Program: impact on awareness of smoking-related perioperative complications and smoking behavior in Northern Canadian communities. J Prim Care Community Health 2016;7:16-23.
162. Cropley M, Theadom A, Pravettoni G, Webb G. The effectiveness of smoking cessation interventions prior to surgery: a systematic review. Nicotine Tob Res 2008;10:407-412.
163. Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population study. Addiction 2014;109:491-499.
164. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012;10:CD008286.
165. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2012;12:CD009670.
166. Hughes JR. Dependence potential and abuse liability of nicotine replacement therapies. Biomed Pharmacother 1989;43:11-17.
167. Moore TJ, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011;6:e27016.
168. Thomas KH, Martin RM, Davies NM, et al. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ 2013;347:f5704.
169. Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015;350:h1109.
170. Hollands GJ, McDermott MS, Lindson-Hawley N, et al. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev 2015;2:CD009164.
171. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;5:CD009329.
172. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009;169:2148-2155.
173. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA 2014;311:193-194.
174. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012;11:CD000146.
175. Fiore MC, Jaen CR, Baker TB, et al. Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update. Available at: http://www.ncbi.nlm.nih.gov/books/NBK63952/. Accessed October 17, 2016.
176. Benowitz NL, Jacob P 3rd, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303.
177. Benowitz NL, Porchet H, Sheiner L, Jacob P 3rd. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988;44:23-28.
178. Benowitz NL, Jacob P 3rd, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 1987;41:467-473.
179. Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28-41.
180. Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001;37:1297-1302.
181. Hubbard R, Lewis S, Smith C, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005;14:416-421.
182. Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005;95:976-978.
183. Warren GW, Singh AK. Nicotine and lung cancer. J Carcinog 2013;12:1.
184. Martinez-Garcia E, Irigoyen M, Gonzalez-Moreno O, et al. Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci 2010;116:467-476.
185. Maier CR, Hollander MC, Hobbs EA, et al. Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. Cancer Prev Res (Phila) 2011;4:1743-1751.
186. Murphy SE, von Weymarn LB, Schutten MM, et al. Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced lung tumorigenesis. Cancer Prev Res (Phila) 2011;4:1752-1760.
187. Stepanov I, Carmella SG, Briggs A, et al. Presence of the carcinogen N'-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009;69:8236-8240.
188. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res 2009;11:1076-1082.
189. Shields PG. Long-term nicotine replacement therapy: cancer risk in context. Cancer Prev Res (Phila) 2011;4:1719-1723.
190. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-3477.
191. Mills EJ, Wu P, Lockhart I, et al. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med 2012;44:588-597.
192. Cahill K, Stead L F, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103.
193. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507-2520.
194. Price S, Hitsman B, Veluz-Wilkins A, et al. The use of varenicline to treat nicotine dependence among patients with cancer [published online ahead of print May 24, 2016. Psycho-Oncology, doi: 10.1002/pon.4166.
195. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 2015;313:687-694.
196. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71.
197. Hajek P, McRobbie H, Myers Smith K, et al. Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial. JAMA Intern Med 2015;175:266-271.
198. Gonzales D, Hajek P, Pliamm L, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther 2014;96:390-396.
199. Lerman C, Schnoll RA, Hawk LW Jr, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2015;3:131-138.
200. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63.
201. Williams KE, Reeves KR, Billing CB Jr, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793-801.
202. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013;159:390-400.
203. Prochaska JJ, Hilton J F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012;344:e2856.
204. Svanstrom H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012;345:e7176.
205. Sharma A, Thakar S, Lavie CJ, et al. Cardiovascular adverse events associated with smoking-cessation pharmacotherapies. Curr Cardiol Rep 2015;17:554.
206. Chelladurai Y, Singh S. Varenicline and cardiovascular adverse events: a perspective review. Ther Adv Drug Saf 2014;5:167-172.
207. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-1366.
208. Kotz D, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med 2015;3:761-768.
209. FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking. U.S. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm436494.htm. Accessed October 17, 2016.
210. Serafini A, Crespel A, Velizara R, Gelisse P. Varenicline-induced grand mal seizure. Epileptic Disord 2010;12:338.
211. Stapleton J, West R, Hajek P, et al. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction 2013;108:2193-2201.
212. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-691.
213. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007;27:380-386.
214. Hughes JR, Stead L F, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014;1:CD000031.
215. van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 2013;8:CD006102.
216. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001;135:423-433.
217. Englisch S, Morgen K, Meyer-Lindenberg A, Zink M. Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature. Clin Neuropharmacol 2013;36:203-215.
218. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014;312:155-161.
219. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med 2014;12:172.
220. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med 2013;11:140.
221. Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 2014;171:1199-1205.
222. Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014;311:155-163.
223. Aveyard P, Johnson C, Fillingham S, et al. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008;336:1223-1227.
224. Klemp I, Steffenssen M, Bakholdt V, et al. Counseling is effective for smoking cessation in head and neck cancer patients - a systematic review and meta-analysis. J Oral Maxillofac Surg 2016;74:1687-1694.
225. Hall SM, Humfleet GL, Munoz RF, et al. Using extended cognitive behavioral treatment and medication to treat dependent smokers. Am J Public Health 2011;101:2349-2356.
226. Hall SM, Humfleet GL, Munoz RF, et al. Extended treatment of older cigarette smokers. Addiction 2009;104:1043-1052.
227. Killen JD, Fortmann S P, Schatzberg AF, et al. Extended cognitive behavior therapy for cigarette smoking cessation. Addiction 2008;103:1381-1390.
228. Yalcin BM, Unal M, Pirdal H, Karahan TF. Effects of an anger management and stress control program on smoking cessation: a randomized controlled trial. J Am Board Fam Med 2014;27:645-660.
229. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007;9:315-327.
230. McLaughlin I, Dani JA, De Biasi M. Nicotine withdrawal. Curr Top Behav Neurosci 2015;24:99-123.
231. Shiffman S, Patten C, Gwaltney C, et al. Natural history of nicotine withdrawal. Addiction 2006;101:1822-1832.
232. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2013;8:CD002850.
233. Civljak M, Stead L F, Hartmann-Boyce J, et al. Internet-based interventions for smoking cessation. Cochrane Database Syst Rev 2013;7:CD007078.
234. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005:CD001007.
235. Lancaster T, Stead L F. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005:CD001292.
236. Hartmann-Boyce J, Lancaster T, Stead L F. Print-based self-help interventions for smoking cessation. Cochrane Database Syst Rev 2014;6:CD001118.
237. Whittaker R, McRobbie H, Bullen C, et al. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev 2012;11:CD006611.
238. Free C, Knight R, Robertson S, et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 2011;378:49-55.
239. Abroms LC, Boal AL, Simmens SJ, et al. A randomized trial of Text2Quit: a text messaging program for smoking cessation. Am J Prev Med 2014;47:242-250.
240. Abroms LC, Padmanabhan N, Thaweethai L, Phillips T. iPhone apps for smoking cessation: a content analysis. Am J Prev Med 2011;40:279-285.
241. Sampson L, Papadakos J, Milne V, et al. Preferences for the provision of smoking cessation education among cancer patients [published online ahead of print April 13, 2016. J Cancer Educ, in press.
242. Smith SS, Keller PA, Kobinsky KH, et al. Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant. Nicotine Tob Res 2013;15:718-728.
243. Mehnert A, Kuhnt S, Brahler E, et al. Twelve-month prevalence of mental disorders in cancer patients across major tumor entities [abstract]. J Clin Oncol 2015;33(Suppl):Abstract 9552.
244. Singer S, Das-Munshi J, Brahler E. Prevalence of mental health conditions in cancer patients in acute care - a meta-analysis. Ann Oncol 2010;21:925-930.
245. Mehnert A, Brahler E, Faller H, et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 2014;32:3540-3546.
246. Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2015;3:CD006936.
247. Spencer JC, Wheeler SB. A systematic review of Motivational Interviewing interventions in cancer patients and survivors. Patient Educ Couns 2016;99:1099-1105.
248. Brandon TH, Goniewicz ML, Hanna NH, et al. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. J Clin Oncol 2015;33:952-963.
249. Bhatnagar A, Whitsel L P, Ribisl KM, et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation 2014;130:1418-1436.
250. U.S. Preventive Services Task Force. Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions. Available at: http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1?ds=1&s=tobacco. Accessed July 15, 2016.
251. Borderud SP, Li Y, Burkhalter JE, et al. Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes. Cancer 2014;120:3527-3535.
252. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013;382:1629-1637.
253. McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014;12:CD010216.
254. Rahman MA, Hann N, Wilson A, et al. E-cigarettes and smoking cessation: evidence from a systematic review and meta-analysis. PLoS One 2015;10:e0122544.
255. Brown J, Beard E, Kotz D, et al. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction 2014;109:1531-1540.
256. McQueen N, Partington EJ, Harrington K F, et al. Smoking cessation and electronic cigarette use among head and neck cancer patients. Otolaryngol Head Neck Surg 2016;154:73-79.
257. Ussher MH, Taylor AH, Faulkner GE. Exercise interventions for smoking cessation. Cochrane Database Syst Rev 2014;8:CD002295.
258. White AR, Rampes H, Liu J P, et al. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2014;1:CD000009.
259. Abbot NC, Stead LF, White AR, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 2000:CD001008.
260. Barnes J, Dong CY, McRobbie H, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 2010:CD001008.